{"id":72847,"date":"2025-01-14T17:04:48","date_gmt":"2025-01-14T16:04:48","guid":{"rendered":"https:\/\/www.embl.org\/news\/?p=72847"},"modified":"2025-06-10T10:55:13","modified_gmt":"2025-06-10T08:55:13","slug":"researchers-uncover-what-drives-aggressive-bone-cancer","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/","title":{"rendered":"Researchers uncover what drives aggressive bone cancer"},"content":{"rendered":"\n<article class=\"vf-card vf-card--brand vf-card--bordered vf-u-margin__bottom--800\" default>\n  <div class=\"vf-card__content | vf-stack vf-stack--400\">\n      <h3 class=\"vf-card__heading\">\n      Summary    <\/h3>\n                <p class=\"vf-card__text\"><ul>\r\n \t<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Large-scale analysis of patient cohorts reveals a novel mechanism driving osteosarcoma, an aggressive paediatric bone cancer.<\/span><\/li>\r\n \t<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The researchers show that this mechanism occurs in approximately 50% of high-grade osteosarcoma cases.<\/span><\/li>\r\n \t<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">This research also provides insights to help predict osteosarcoma patient outcomes which can help improve the management of this disease.<\/span><\/li>\r\n<\/ul><\/p>\n      <\/div>\n<\/article>\n\n\n\n\n<p>Osteosarcoma is a type of aggressive bone cancer that most commonly affects children and young adults between the ages of 10 and 20, during times of rapid bone growth. Although rare, it has a significant impact on young people and their families as treatment can require surgery or amputation. The cancer also has the potential to spread to other organs, most commonly the lungs. Because osteosarcoma is so genomically complex, it has been challenging to identify what genetic mutations drive the disease. As a result, there has been little advancement in treatment options over the past 40 years.&nbsp;<\/p>\n\n\n\n<p>New research, <a href=\"https:\/\/www.cell.com\/cell\/fulltext\/S0092-8674(24)01418-1\">published in the journal <em>Cell<\/em><\/a>, solves the mystery of what drives the genomic rearrangements causing the aggressive development and evolution of osteosarcoma tumours. By analysing the largest collection of whole-genome data from osteosarcoma patients, the researchers identified a new mutation mechanism, called loss-translocation-amplification (LTA) chromothripsis, which is present in approximately 50% of high-grade osteosarcoma cases.&nbsp;<\/p>\n\n\n\n<p>This finding explains the unique biology that makes this tumour type so aggressive and the high levels of genomic instability observed in osteosarcoma cancer cells. The study also presents a prognostic biomarker \u2013 a biological characteristic of cancer cells that can help predict patient outcome \u2013 that might be used to anticipate the likely course of the disease.&nbsp;<\/p>\n\n\n\n<p>This work is a collaboration between researchers at EMBL\u2019s European Bioinformatics Institute (EMBL-EBI), <a href=\"https:\/\/www.ucl.ac.uk\/\">University College London (UCL)<\/a>, the <a href=\"https:\/\/www.rnoh.nhs.uk\/\">Royal National Orthopaedic Hospital<\/a>, and the R&amp;D laboratory of <a href=\"https:\/\/www.genomicsengland.co.uk\/\">Genomics England<\/a>.&nbsp;&nbsp;<\/p>\n\n\n\n<p>&#8220;We&#8217;ve known for years that osteosarcoma cells have some of the most complex genomes seen in human cancers, but we couldn&#8217;t explain the mechanisms behind this,&#8221; said <a href=\"https:\/\/www.ebi.ac.uk\/people\/person\/isidro-cortes-ciriano\/\">Isidro Cortes-Ciriano, Group Leader at EMBL-EBI<\/a> and co-senior author of the study. &#8220;By studying the genetic abnormalities in different regions of each tumour and using new technologies that let us read long stretches of DNA, we&#8217;ve been able to understand how chromosomes break and rearrange, and how this impacts osteosarcoma disease progression.&#8221;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Large-scale genomic analysis<\/h2>\n\n\n\n<p>This study analysed multiple regions from each osteosarcoma tumour using long-read sequencing. This approach was crucial in identifying the LTA chromothripsis mechanism and discovering that chromosomes rearranged in cancer cells continue to acquire additional abnormalities as cancer progresses. This helps tumours evade treatment.&nbsp;&nbsp;<\/p>\n\n\n\n<p>The researchers also analysed whole-genome sequencing data from over 5,300 tumours from diverse cancer types. Through this broader analysis, the researchers identified that very complex chromosomal abnormalities in various cancers arise because chromosomes affected by chromothripsis are highly unstable. This finding has significant implications for the treatment of diverse cancer types, suggesting that the genomic instability of complex chromosomes seen in osteosarcoma progression is also relevant to other cancers.<\/p>\n\n\n\n<p>\u201cOur additional analysis of different tumour types has shown that chromosomes affected by complex genomic rearrangements are also common and unstable in other cancers,\u201d said Jose Espejo Valle-Inclan, co-first author of the study and former postdoctoral fellow at EMBL-EBI, currently Group Leader at the Botton-Champalimaud Pancreatic Cancer Centre. \u201cThis has a huge impact on our overall understanding of cancer development, highlighting the importance of investing in studies that explore these mechanisms.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Predicting prognosis&nbsp;<\/h2>\n\n\n\n<p>Predicting the prognosis \u2013 the likely course of the disease \u2013 for osteosarcoma patients remains a major unmet need. As part of this study, the team also presented a novel prognostic biomarker for osteosarcoma: loss of heterozygosity (LOH). LOH occurs when one copy of a genomic region is lost. In osteosarcoma, a high degree of LOH across the genome predicts a lower survival probability.&nbsp;<\/p>\n\n\n\n<p>&#8220;This biomarker could help us identify patients who are unlikely to benefit from treatment which can have very unpleasant effects and which patients find difficult to tolerate,\u201d said <a href=\"https:\/\/profiles.ucl.ac.uk\/3212-adrienne-flanagan\">Adrienne Flanagan, Professor at UCL<\/a>, <a href=\"https:\/\/www.rnoh.nhs.uk\/health-professionals\/consultants\/professor-adrienne-m-flanagan\">Consultant Histopathologist at RNOH<\/a>, and co-senior author of the study. \u201cThis is invaluable for providing patients with more tailored treatments and help spare unnecessary effects of toxic therapies.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">United efforts<\/h2>\n\n\n\n<p>This research used data from the <a href=\"https:\/\/www.genomicsengland.co.uk\/initiatives\/100000-genomes-project\">100,000 Genomes Project<\/a>, a pioneering study led by Genomics England and NHS England that sequenced whole genomes from NHS patients affected by rare conditions or cancer. By analysing genomic data from a large cohort of osteosarcoma patients, the researchers uncovered the prevalence of LTA chromothripsis in approximately 50% of both paediatric and adult high-grade osteosarcomas. However, it very rarely occurs in other cancer types, thus highlighting the need for large-scale analysis of rare cancers to identify the distinct mutations that underpin their evolution.<\/p>\n\n\n\n<p>\u201cThese discoveries go a long way towards improving our understanding of what drives the progression of this aggressive type of bone cancer and how it may develop in a patient,\u201d said Greg Elgar, Director of Sequencing R&amp;D at Genomics England. \u201cThe new insights could, with time, lead to better treatment options and outcomes for patients through more targeted care. The research shows what can be achieved when academia, clinical practice, and the NHS work together and combine research and development efforts across these three streams.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">A novel mutational process<\/h2>\n\n\n\n<p>LTA chromothripsis starts when a double-strand break in DNA leads to the loss of a crucial tumour suppressor gene known as <em>TP53<\/em>, which normally helps prevent cancer initiation. The loss of <em>TP53<\/em> triggers the DNA to rearrange and amplify incorrectly, causing multiple copies across different chromosomes of genes that drive cancer growth. As a result, normal bone cells rapidly transform into aggressive cancer cells. This leads to fast tumour development and progression.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Funding and support<\/h2>\n\n\n\n<p>This research was made possible thanks to funding from several organisations dedicated to improving our understanding of osteosarcoma and other paediatric cancers.&nbsp;<\/p>\n\n\n\n<p>Funding was received from EMBL, The Sarcoma Foundation of America, the Pathological Society of Great Britain and Ireland, and the Jean Shanks Foundation that funded Dr Solange DeNoon, a pathology PhD student at UCL Cancer Institute.<\/p>\n\n\n\n<p>Funding for this work was also received from The Tom Prince Cancer Trust, a charity established in memory of Tom Prince, who sadly passed away from osteosarcoma at the age of 15 in 2004. Founded by Tom&#8217;s parents, Clinton and Adele Prince, the Trust <a href=\"https:\/\/www.ucl.ac.uk\/cancer\/news\/2018\/tom-prince-trust-donation-osteosarcoma-project\">raised more than \u00a31 million over 13 years, which was donated to UCL to establish the Tom Prince Osteosarcoma Research Project<\/a>.<\/p>\n\n\n\n<p>All these contributions show how much we can learn about a disease when adequate funding is provided leading to discoveries that improve patient outcomes and offer hope to affected families.<\/p>\n\n\n\n<p>Provision of patients\u2019 samples from the RNOH was made possible through the Royal National Orthopaedic Hospital Pathology Department and the Research and Development Department, The Rosetrees Trust, Skeletal Cancer Trust, Sarcoma UK, The Bone Cancer Research Trust and The Pathological Society of Great Britain and Ireland.<\/p>\n\n\n\n<p>The project was also supported by the National Institute for Health Research, UCLH Biomedical Research Centre, and UCL Experimental Cancer Centre.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Thank you&nbsp;<\/h2>\n\n\n\n<p>The scientists involved in this study would like to thank all of the patients and their families who donated samples used in this research.&nbsp;<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"vf-divider\"\/>\n\n\n\n<h1 class=\"wp-block-heading\" id=\"Spanish\"><strong>Cient\u00edficos espa\u00f1oles descubren los factores que impulsan el c\u00e1ncer de hueso agresivo<\/strong><\/h1>\n\n\n\n<p><strong><em>El estudio identifica un nuevo mecanismo mutacional que acelera el osteosarcoma y un biomarcador que podr\u00eda ayudar a predecir el curso que podr\u00eda tener la enfermedad en los pacientes<\/em><\/strong><\/p>\n\n\n\n<article class=\"vf-card vf-card--brand vf-card--bordered vf-u-margin__bottom--800\" default>\n  <div class=\"vf-card__content | vf-stack vf-stack--400\">\n      <h3 class=\"vf-card__heading\">\n      Resumen    <\/h3>\n                <p class=\"vf-card__text\"><!-- wp:list -->\r\n<ul class=\"wp-block-list\">\r\n \t<li style=\"list-style-type: none;\">\r\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\r\n \t<li>Un estudio de cohortes a gran escala revela un nuevo mecanismo que impulsa el osteosarcoma, un c\u00e1ncer \u00f3seo pedi\u00e1trico agresivo.<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<!-- \/wp:list-item --> <!-- wp:list-item -->\r\n<ul class=\"wp-block-list\">\r\n \t<li style=\"list-style-type: none;\">\r\n<ul class=\"wp-block-list\">\r\n \t<li>Los investigadores muestran que este mecanismo ocurre en aproximadamente el 50% de los casos de osteosarcoma de grado alto.<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<!-- \/wp:list-item --> <!-- wp:list-item -->\r\n<ul class=\"wp-block-list\">\r\n \t<li style=\"list-style-type: none;\">\r\n<ul class=\"wp-block-list\">\r\n \t<li>Este estudio ayudar\u00e1 a predecir el curso de la enfermedad a partir de los resultados de los pacientes, lo que puede mejorar la gesti\u00f3n del tratamiento.<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ul>\r\n<!-- \/wp:list-item --><\/p>\n      <\/div>\n<\/article>\n\n\n\n\n<p>El osteosarcoma es un tipo de c\u00e1ncer \u00f3seo agresivo que afecta principalmente a ni\u00f1os y j\u00f3venes entre los 10 y los 20 a\u00f1os, especialmente durante periodos de r\u00e1pido crecimiento \u00f3seo. Aunque es poco com\u00fan, tiene un impacto significativo en los j\u00f3venes y sus familias, ya que su tratamiento generalmente requiere&nbsp; quimioterapia, cirug\u00eda o amputaci\u00f3n. Adem\u00e1s, este c\u00e1ncer tiene el potencial de expandirse a otros \u00f3rganos, principalmente a los pulmones. Durante los \u00faltimos 40 a\u00f1os ha habido pocos avances en el estudio de esta enfermedad, ya que el osteosarcoma tiene una gen\u00f3mica compleja y esto dificulta identificar las mutaciones gen\u00e9ticas que lo causan. Como resultado, las opciones terap\u00e9uticas para osteosarcoma no han cambiado en d\u00e9cadas.&nbsp;<\/p>\n\n\n\n<p>Una nueva investigaci\u00f3n, publicada en la revista <em>Cell<\/em>, resuelve el misterio sobre las causas de las reordenaciones gen\u00f3micas que impulsan el desarrollo agresivo y la evoluci\u00f3n de los tumores de osteosarcoma. Los investigadores generaron&nbsp; la mayor base de datos de genomas completos de pacientes con osteosarcoma e identificaron un nuevo mecanismo mutacional, denominado cromotripsis por p\u00e9rdida-translocaci\u00f3n-amplificaci\u00f3n (LTA, por sus siglas en ingl\u00e9s), presente en aproximadamente el 50 % de los casos de osteosarcoma de grado alto.<\/p>\n\n\n\n<p>Este hallazgo explica la complejidad biol\u00f3gica que hace que este tipo de tumor sea tan agresivo y ayuda a entender los altos niveles de inestabilidad gen\u00f3mica observados en las c\u00e9lulas cancerosas del osteosarcoma. Adem\u00e1s, el estudio presenta un biomarcador pron\u00f3stico \u2013una caracter\u00edstica biol\u00f3gica de las c\u00e9lulas cancerosas que ayuda a predecir el desenlace de la enfermedad\u2013 y que podr\u00eda ser utilizado para anticipar su curso probable.<\/p>\n\n\n\n<p>Este trabajo es una colaboraci\u00f3n entre investigadores del Instituto Europeo de Bioinform\u00e1tica del EMBL (EMBL-EBI), el <em>University College London<\/em> (UCL), el <em>Royal National Orthopaedic Hospital<\/em> y el laboratorio de I+D de <em>Genomics England<\/em>.<\/p>\n\n\n\n<p>&#8220;Sabemos desde hace a\u00f1os que las c\u00e9lulas del osteosarcoma tienen algunos de los genomas m\u00e1s complejos observados en c\u00e1nceres humanos, pero no pod\u00edamos explicar los mecanismos detr\u00e1s de esto&#8221;, se\u00f1ala Isidro Cortes-Ciriano, jefe de grupo en EMBL-EBI y coautor principal del estudio. &#8220;Al estudiar las anomal\u00edas gen\u00f3micas en diferentes regiones de cada tumor y usar nuevas tecnolog\u00edas que nos permiten leer secuencias largas de ADN, hemos podido comprender c\u00f3mo los cromosomas se rompen y reorganizan, y c\u00f3mo esto impacta en la progresi\u00f3n de la enfermedad&#8221;.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">An\u00e1lisis gen\u00f3mico a gran escala<\/h2>\n\n\n\n<p>El estudio analiz\u00f3 m\u00faltiples regiones de cada tumor de osteosarcoma utilizando secuenciaci\u00f3n de lectura larga (<em>long-read sequencing<\/em>). Este enfoque fue clave para identificar el mecanismo de cromotripsis LTA y descubrir que los cromosomas reordenados en las c\u00e9lulas cancerosas siguen adquiriendo anomal\u00edas adicionales a medida que el c\u00e1ncer progresa, ayudando a los tumores a evadir el tratamiento.<\/p>\n\n\n\n<p>Los investigadores tambi\u00e9n analizaron datos de secuenciaci\u00f3n de genomas completos de m\u00e1s de 5,300 tumores de diversos tipos de c\u00e1ncer. A trav\u00e9s de este an\u00e1lisis m\u00e1s amplio, descubrieron que las anomal\u00edas cromos\u00f3micas complejas en diferentes c\u00e1nceres surgen debido a que los cromosomas afectados por la cromotripsis son altamente inestables, lo que reduce la eficacia de diversos tratamientos. Este hallazgo tiene implicaciones significativas para el tratamiento de diversos tipos de c\u00e1ncer, sugiriendo que la inestabilidad gen\u00f3mica observada en el osteosarcoma es tambi\u00e9n relevante para otros c\u00e1nceres.<\/p>\n\n\n\n<p>&#8220;Nuestro an\u00e1lisis adicional de diferentes tipos de tumores ha mostrado que los cromosomas afectados por reordenamientos gen\u00f3micos complejos son tambi\u00e9n comunes e inestables en otros tipos de c\u00e1ncer&#8221;, asegura Jos\u00e9 Espejo Valle-Incl\u00e1n, coautor principal del estudio y ex investigador postdoctoral en EMBL-EBI, actualmente jefe de grupo en el Centro de C\u00e1ncer Pancre\u00e1tico Botton-Champalimaud. &#8220;Esto tiene un enorme impacto en nuestra comprensi\u00f3n general del desarrollo del c\u00e1ncer, destacando la importancia de invertir en estudios que exploren estos mecanismos&#8221;.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Esfuerzo conjunto<\/h2>\n\n\n\n<p>Esta investigaci\u00f3n utiliz\u00f3 datos del <em>Proyecto de los 100,000 Genomas<\/em>, un estudio pionero liderado por <em>Genomics England<\/em> y el NHS de Inglaterra que secuenci\u00f3 genomas completos de pacientes con enfermedades raras o c\u00e1ncer. Al analizar datos gen\u00f3micos y cl\u00ednicos de cientos de pacientes con osteosarcoma, los investigadores descubrieron la prevalencia de la cromotripsis LTA en aproximadamente el 50 % de los casos de osteosarcoma de grado alto, tanto pedi\u00e1tricos como adultos. Sin embargo, este mecanismo ocurre muy raramente en otros tipos de c\u00e1ncer, lo que subraya la necesidad de desarrollar an\u00e1lisis a gran escala en c\u00e1nceres raros para identificar las mutaciones espec\u00edficas que impulsan su evoluci\u00f3n.<\/p>\n\n\n\n<p>&#8220;Estos descubrimientos avanzan significativamente nuestra comprensi\u00f3n de lo que impulsa la progresi\u00f3n de este tipo agresivo de c\u00e1ncer \u00f3seo y c\u00f3mo puede desarrollarse en un paciente&#8221;, se\u00f1ala Greg Elgar, Director de I+D en Secuenciaci\u00f3n en <em>Genomics England<\/em>. &#8220;Estas nuevas perspectivas podr\u00edan, con el tiempo, llevar a mejores opciones de tratamiento y resultados para los pacientes a trav\u00e9s de un cuidado m\u00e1s personalizado&#8221;.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Predicci\u00f3n del pron\u00f3stico de los pacientes de osteosarcoma<\/h2>\n\n\n\n<p>Predecir el pron\u00f3stico \u2013el curso probable de la enfermedad\u2013 para los pacientes con osteosarcoma sigue siendo una necesidad no cubierta. Como parte de este estudio, el equipo present\u00f3 un nuevo biomarcador pron\u00f3stico: la p\u00e9rdida de heterocigosidad (LOH, por sus siglas en ingl\u00e9s). La LOH ocurre cuando se pierde una copia de una regi\u00f3n gen\u00f3mica. En el osteosarcoma, un alto grado de LOH en el genoma predice una menor probabilidad de supervivencia.<\/p>\n\n\n\n<p>&#8220;Este biomarcador podr\u00eda ayudarnos a identificar a los pacientes que probablemente no se beneficiar\u00e1n de tratamientos con efectos secundarios muy desagradables y dif\u00edciles de tolerar&#8221;, dijo Adrienne Flanagan, profesora en UCL, consultora histopat\u00f3loga en RNOH y coautora principal del estudio. &#8220;Esto es important\u00edsimo para proporcionar a los pacientes tratamientos m\u00e1s personalizados y evitarles los efectos innecesarios de terapias t\u00f3xicas&#8221;.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Un proceso mutacional novedoso<\/h2>\n\n\n\n<p>La cromotripsis LTA comienza cuando una rotura de doble hebra en el ADN provoca la p\u00e9rdida de un gen supresor tumoral clave conocido como <em>TP53<\/em>, que normalmente ayuda a prevenir la iniciaci\u00f3n del c\u00e1ncer. La p\u00e9rdida de <em>TP53<\/em> desencadena la reordenaci\u00f3n y amplificaci\u00f3n incorrecta del ADN, causando m\u00faltiples copias de oncogenes (genes impulsores del c\u00e1ncer) en diferentes cromosomas. Como resultado, las c\u00e9lulas \u00f3seas normales se transforman r\u00e1pidamente en c\u00e9lulas cancerosas agresivas, lo que lleva a un desarrollo y progresi\u00f3n tumoral r\u00e1pidos.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Financiaci\u00f3n y apoyo<\/h2>\n\n\n\n<p>Este estudio ha sido posible gracias a la financiaci\u00f3n de varias organizaciones dedicadas a mejorar nuestra comprensi\u00f3n del osteosarcoma y otros c\u00e1nceres pedi\u00e1tricos.<\/p>\n\n\n\n<p>La financiaci\u00f3n para este trabajo fue proporcionada por el EMBL, la <em>Sarcoma Foundation of America<\/em>, la <em>Pathological Society of Great Britain and Ireland<\/em>, y la <em>Jean Shanks Foundation<\/em>, que financi\u00f3 a la Dra. Solange DeNoon, estudiante de doctorado en patolog\u00eda en el Instituto del C\u00e1ncer de la UCL.<\/p>\n\n\n\n<p>Tambi\u00e9n se recibi\u00f3 financiaci\u00f3n del <em>Tom Prince Cancer Trust<\/em>, una organizaci\u00f3n ben\u00e9fica establecida en memoria de Tom Prince, quien lamentablemente falleci\u00f3 de osteosarcoma a los 15 a\u00f1os en 2004. Fundada por los padres de Tom, Clinton y Adele Prince, la fundaci\u00f3n<a href=\"https:\/\/www.ucl.ac.uk\/cancer\/news\/2018\/tom-prince-trust-donation-osteosarcoma-project\"> recaud\u00f3 m\u00e1s de \u00a31 mill\u00f3n durante 13 a\u00f1os, que fueron donados a la UCL<\/a> para establecer el <em>Tom Prince Osteosarcoma Research Project<\/em>.<\/p>\n\n\n\n<p>Estas contribuciones demuestran cu\u00e1nto se puede aprender sobre una enfermedad cuando se dispone de una financiaci\u00f3n adecuada, lo que permite descubrimientos que mejoran los resultados para los pacientes y ofrecen esperanza a las familias afectadas.<\/p>\n\n\n\n<p>La provisi\u00f3n de muestras de pacientes por parte del RNOH fue posible gracias al Departamento de Patolog\u00eda y el Departamento de Investigaci\u00f3n y Desarrollo del <em>Royal National Orthopaedic Hospital<\/em>, as\u00ed como a <em>The Rosetrees Trust<\/em>, <em>Skeletal Cancer Trust<\/em>, <em>Sarcoma UK<\/em>, <em>The Bone Cancer Research Trust<\/em> y la <em>Pathological Society of Great Britain and Ireland<\/em>.<\/p>\n\n\n\n<p>El proyecto tambi\u00e9n cont\u00f3 con el apoyo del Instituto Nacional de Investigaci\u00f3n en Salud (NIHR), el Centro de Investigaci\u00f3n Biom\u00e9dica UCLH y el Centro Experimental de C\u00e1ncer de la UCL.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Agradecimientos<\/h2>\n\n\n\n<p>Los cient\u00edficos agradecen especialmente a los pacientes y familias que donaron muestras utilizadas en esta investigaci\u00f3n.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes.<\/p>\n","protected":false},"author":77,"featured_media":72849,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[11060,17591],"tags":[28,38,17275,36,42,5686,539],"embl_taxonomy":[11080,2906],"class_list":["post-72847","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-highlights","category-science-technology","tag-bioinformatics","tag-cancer","tag-cortes-ciriano","tag-embl-ebi","tag-genomics","tag-rare-disease","tag-research-highlight","embl_taxonomy-cortes-ciriano-group","embl_taxonomy-embl-ebi"],"acf":{"vfwp-news_embl_taxonomy":[11080,2906],"featured":true,"show_featured_image":false,"field_target_display":"both","field_article_language":{"value":"english","label":"English"},"article_intro":"<p>Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes<\/p>\n","related_links":[{"link_description":"What happens when chromosomes shatter","link_url":"https:\/\/www.ebi.ac.uk\/about\/news\/research-highlights\/what-happens-during-chromothripsis\/"}],"source_article":[{"publication_title":"Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution ","publication_link":{"title":"","url":"https:\/\/www.cell.com\/cell\/fulltext\/S0092-8674(24)01418-1","target":""},"publication_authors":"Valle-Inclan JE.,","publication_source":"Cell","publication_date":"14 January 2025","publication_doi":"10.1016\/j.cell.2024.12.005"}],"in_this_article":false,"press_contact":"EMBL-EBI Generic","article_translations":[{"translation_language":"Espa\u00f1ol","translation_anchor":"#Spanish"}],"languages":""},"embl_taxonomy_terms":[{"uuid":"a:3:{i:0;s:36:\"302cfdf7-365b-462a-be65-82c7b783ebf7\";i:1;s:36:\"442a4893-2c31-4523-b9eb-fb1ee4bd2037\";i:2;s:36:\"c365de00-bbe7-41f8-978d-1b967a5221b1\";}","parents":[],"name":["Cortes Ciriano Group"],"slug":"cortes-ciriano-group","description":"What &gt; EMBL-EBI Research &gt; Cortes Ciriano Group"},{"uuid":"a:3:{i:0;s:36:\"b14d3f13-5670-44fb-8970-e54dfd9c921a\";i:1;s:36:\"89e00fee-87f4-482e-a801-4c3548bb6a58\";i:2;s:36:\"a99d1a7c-ca83-4c00-ab61-d082d3e41ce3\";}","parents":[],"name":["EMBL-EBI"],"slug":"embl-ebi","description":"Where &gt; All EMBL sites &gt; EMBL-EBI"}],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Researchers uncover what drives aggressive bone cancer | EMBL<\/title>\n<meta name=\"description\" content=\"Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Researchers uncover what drives aggressive bone cancer | EMBL\" \/>\n<meta property=\"og:description\" content=\"Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-14T16:04:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-10T08:55:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Vicky Hatch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Vicky Hatch\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/\"},\"author\":{\"name\":\"Vicky Hatch\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/d8477ba2d7a6164b141a3872a25ee982\"},\"headline\":\"Researchers uncover what drives aggressive bone cancer\",\"datePublished\":\"2025-01-14T16:04:48+00:00\",\"dateModified\":\"2025-06-10T08:55:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/\"},\"wordCount\":2603,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg\",\"keywords\":[\"bioinformatics\",\"cancer\",\"cortes-ciriano\",\"embl-ebi\",\"genomics\",\"rare disease\",\"research highlight\"],\"articleSection\":[\"Research highlights\",\"Science &amp; Technology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/\",\"url\":\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/\",\"name\":\"Researchers uncover what drives aggressive bone cancer | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg\",\"datePublished\":\"2025-01-14T16:04:48+00:00\",\"dateModified\":\"2025-06-10T08:55:13+00:00\",\"description\":\"Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg\",\"width\":1000,\"height\":600,\"caption\":\"A new mutation mechanism driving osteosarcoma. Image credit: Karen Arnott\/EMBL-EBI\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/d8477ba2d7a6164b141a3872a25ee982\",\"name\":\"Vicky Hatch\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6d864d58088d9e60f42c501aa30714d303efc1ca5aed268210905409910b90d5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6d864d58088d9e60f42c501aa30714d303efc1ca5aed268210905409910b90d5?s=96&d=mm&r=g\",\"caption\":\"Vicky Hatch\"},\"url\":\"https:\/\/www.embl.org\/news\/author\/vicky-hatch-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2--2\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Researchers uncover what drives aggressive bone cancer | EMBL","description":"Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Researchers uncover what drives aggressive bone cancer | EMBL","og_description":"Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes.","og_url":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2025-01-14T16:04:48+00:00","article_modified_time":"2025-06-10T08:55:13+00:00","og_image":[{"width":1000,"height":600,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg","type":"image\/jpeg"}],"author":"Vicky Hatch","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Vicky Hatch","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/"},"author":{"name":"Vicky Hatch","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/d8477ba2d7a6164b141a3872a25ee982"},"headline":"Researchers uncover what drives aggressive bone cancer","datePublished":"2025-01-14T16:04:48+00:00","dateModified":"2025-06-10T08:55:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/"},"wordCount":2603,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg","keywords":["bioinformatics","cancer","cortes-ciriano","embl-ebi","genomics","rare disease","research highlight"],"articleSection":["Research highlights","Science &amp; Technology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/","url":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/","name":"Researchers uncover what drives aggressive bone cancer | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg","datePublished":"2025-01-14T16:04:48+00:00","dateModified":"2025-06-10T08:55:13+00:00","description":"Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/science-technology\/researchers-uncover-what-drives-aggressive-bone-cancer\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg","width":1000,"height":600,"caption":"A new mutation mechanism driving osteosarcoma. Image credit: Karen Arnott\/EMBL-EBI"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/d8477ba2d7a6164b141a3872a25ee982","name":"Vicky Hatch","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6d864d58088d9e60f42c501aa30714d303efc1ca5aed268210905409910b90d5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6d864d58088d9e60f42c501aa30714d303efc1ca5aed268210905409910b90d5?s=96&d=mm&r=g","caption":"Vicky Hatch"},"url":"https:\/\/www.embl.org\/news\/author\/vicky-hatch-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2-2--2\/"}]}},"field_target_display":"both","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/2024-CORTES-CIRIANO-Osteosarcoma-1000x600-1.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/72847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/77"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=72847"}],"version-history":[{"count":6,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/72847\/revisions"}],"predecessor-version":[{"id":73017,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/72847\/revisions\/73017"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/72849"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=72847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=72847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=72847"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=72847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}